Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

A-H Premium Weekly: CNOOC, Everbright Sec, Sinopec Oilfield

A-H Premium Weekly: Remegen, CNOOC, COSCO Shipping

A-H Premium Weekly: Cansino, Great Wall Motor, Shandong Xinhua

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

China Health care / Quantitative Analysis

<ul>
<li>We analyse the changes of A/H premium on 140 stocks over the last week.</li>
<li>The decline in A-H premium were led by health care and consumer staples, which was offset by the increase in consumer discretionary. </li>
<li>We highlight A-H premium changes in Zhejiang Shibao, PICC, CRRC, Shandong Xinhua, and Shenwan Hongyuan.</li>
</ul>


We analyse the changes of A/H premium on 140 stocks over the last week.
The decline in A-H premium were led by health care and consumer staples, which was offset by the increase in consumer discretionary. 
We highlight A-H premium changes in Zhejiang Shibao, PICC, CRRC, Shandong Xinhua, and Shenwan Hongyuan.


Shanghai Haohai Biological Technology (6826 HK)

Shenzhen HepaLink Pharmaceutical (H) (9989 HK)

A-H Premium Weekly: Zhejiang Shibao, PICC, CRRC